Evidence map›Paper›PMID 30661232›Full record

ArticleJournal of cancer education : the official journal of the American Association for Cancer Education2020

Development and Testing of a Decision Aid for Unaffected Women with a BRCA1 or BRCA2 Mutation.

Terri Jabaley, Meghan L Underhill-Blazey, Donna L Berry

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of cancer education : the official journal of the American Association for Cancer Education, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Decision Aids for Preventive Treatment Alternatives forGeburtshilfe und Frauenheilkunde · 2021
    Article
  11. Review
  12. Genetic testing for hereditary cancer syndromes: patient recommendations for improved risk communication.Health expectations : an international journal of public participation in health care and health policy · 2020
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Terri JabaleyThe Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana Farber Cancer Institute, 375 Longwood Ave., Boston, MA, 02215, USA. theresa_jabaley@dfci.harvard.edu.
Meghan L Underhill-BlazeyThe Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Cancer Genetics and Prevention Program, Dana-Farber Cancer Institute, Boston, MA, USA.
Donna L BerryThe Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana Farber Cancer Institute, 375 Longwood Ave., Boston, MA, 02215, USA.
Dana-Farber Cancer Institute · USCancer Genetics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For women who are unaffected carriers of a pathogenic BRCA mutation, cancer risk management requires ongoing education, counseling, and support from an interdisciplinary team of medical specialists, genetic counselors, and nurses specializing in genomics. The purpose of this study was to develop and pilot test an educational, patient-focused decision aid to facilitate shared decision making. A steering committee developed the prototype aid after an extensive review of the literature. The aid was designed at the ninth-grade reading level, to be consistent with internationally accepted clinical guidelines and inclusive of all risk management options and psychosocial issues important to cancer risk management decision making. The aid was tested with 23 participants: eight experts and 15 end users. Eleven survey items were asked related to organization, clarity, usefulness, comprehensiveness, ease of understanding, and relevance to the cancer risk management decision-making process. Mean scores were 3 or higher on Likert scales of 1-4 (high) for each of the 11 items. Two open-ended questions elicited general comments and suggestions for additions, deletions, or revisions to the decision aid. The steering committee made final revisions to the aid based on participant feedback and committee consensus.

Indexed as

Decision Support TechniquesMutationAdultBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsFemaleGenetic CounselingGenetic TestingHealth StatusHumansMiddle AgedSurveys and QuestionnairesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRCA 1/2Decision aidEducational materialGenetics/genomicsHereditary breast and ovarian cancer syndrome

Identifiers

PMID30661232
OpenAlexW2910124265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.